NMI 900

Drug Profile

NMI 900

Alternative Names: GSK-1070916; GSK1070916A

Latest Information Update: 17 May 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator GlaxoSmithKline
  • Developer Cancer Research UK; Medical Prognosis Institute; Nemucore Medical Innovations
  • Class Antineoplastics; Indoles
  • Mechanism of Action Aurora kinase B inhibitors; Aurora kinase C inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Ovarian cancer
  • Phase I/II Solid tumours

Most Recent Events

  • 11 May 2016 Nemucore plans a phase IIb trial for Ovarian cancer in the US
  • 06 May 2016 Chemical structure information added
  • 20 Jan 2016 Phase-II clinical trials in Ovarian cancer in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top